October 1st 2021CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss the differences in safety profiles between melflufen/dexamethasone and pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.